サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1758196

月経困難症治療の世界市場

Dysmenorrhea Treatment

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.09円
月経困難症治療の世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

月経困難症治療の世界市場は2030年までに91億米ドルに達する見込み

2024年に59億米ドルと推定される月経困難症治療の世界市場は、2024～2030年の分析期間においてCAGR 7.6%で成長し、2030年には91億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである原発性月経困難症は、CAGR 9.1％を記録し、分析期間終了時には60億米ドルに達すると予測されます。二次性月経困難症セグメントの成長率は、分析期間中CAGR 5.0%と推定されます。

米国市場は16億米ドルと推定、中国はCAGR 12.1％で成長予測

米国の月経困難症治療市場は2024年に16億米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 12.1%で推移し、2030年までに20億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.7%と7.3%と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

世界の月経困難症治療市場- 主要動向と促進要因まとめ

なぜ月経困難症は女性の健康において見過ごされなくなったのか？

何十年もの間、月経困難症-一般に月経痛として知られている-は矮小化されたり、過小診断されたりすることが多くなりました。しかし現在では、月経困難症に対する認識が高まり、ヘルスケアへの介入も増加していることから、月経困難症は公衆衛生上の重大な関心事として浮上しています。世界の月経困難者の半数以上が罹患している月経困難症は、不快感の原因であるだけでなく、学校や職場を欠席する主な原因でもあります。このためヘルスケアシステムには社会経済的な大きな圧力がかかり、利害関係者は月経痛を「正常な」女性の経験ではなく、正当な病状としてとらえ直すよう求められています。公衆衛生の取り組みや教育キャンペーンは、スティグマを取り払い、女性に市販の治療薬だけに頼るのではなく、専門家の助けを求めるよう促しています。さらに、ソーシャルメディアやオンラインプラットフォームは、女性の健康に関する会話を増幅させ、月経困難症のような状態を、研究や治療の緊急テーマへと変えています。その累積的な影響として、体系的な診断と的を絞った治療計画の必要性が広く認識されるようになり、月経困難症治療市場の成長に活力を与えています。

世界の業界アナリストは月経痛の治療オプションにどのような進歩を見ているか？

月経困難症の治療法は、従来の非ステロイド性抗炎症薬や経口避妊薬から大きく進化しています。非ステロイド性抗炎症薬はプロスタグランジン誘発の子宮収縮を抑える第一選択薬であることに変わりはありませんが、より長続きし、より即効性のある緩和のために新しい製剤が開発されています。ホルモン治療は、より優れた忍容性とより少ない副作用を提供するために微調整されており、より幅広い層のユーザーに適しています。さらに、経皮パッチや膣リングから神経調節デバイスに至るまで、特にホルモン使用が禁忌の患者を対象とした非ホルモン療法への動向も高まっています。これと並行して、臨床試験で有望視されているハーブエキス、鍼治療、栄養補助食品の使用など、補完医療の研究も進んでいます。徐放性錠剤、温熱パッチ、ドラッグコーティングされたタンポンなどの新しいデリバリーメカニズムも、治療へのアクセスや有効性を拡大しています。このような技術革新は、製品ポートフォリオを多様化させるだけでなく、さまざまな人口層における月経痛の管理方法を再定義しています。

人口動態と意識に基づく世界市場のシフトは？

人口動態の変化と文化の進化は、月経困難症治療への需要を促進する上で極めて重要な役割を果たしています。若い世代、特にZ世代とミレニアル世代は、月経の健康についてより健康意識が高く、積極的で、痛みを黙って我慢するよりも医療サポートを求めることが多いです。このような行動の変化はヘルスケア提供者にも反映されており、ヘルスケア提供者は月経困難症を明確な臨床的実体として診断し治療する傾向が強くなっています。北米や欧州のような先進地域では、先進的なヘルスケア制度と保険適用が、早期診断と治療の継続を支えています。一方、アジア太平洋、ラテンアメリカ、アフリカの新興国では、ヘルスケアへのアクセスの改善、政府主導の健康教育キャンペーン、婦人科医の増加によって需要が高まっています。さらに、農村部の人々の都市化により、OTC製品やデジタル診察へのアクセスが改善され、女性がより簡単に治療の選択肢を検討できるようになっています。製薬会社もこうした地域でのマーケティング活動を強化しており、多くの場合、地域の嗜好や文化的感受性に合わせて製品を調整しています。このような地理的・人口統計的多様化により、より包括的で広範な市場展開が促進されています。

月経困難症治療市場の成長を加速させている要因とは？

月経困難症治療市場の成長は、いくつかの要因によって牽引されています。製剤およびドラッグデリバリーシステムの技術的進歩により、有効性と患者のコンプライアンスが大幅に向上しています。月経障害に対する認識の高まりとデスティグマティゼーションによる診断率の上昇により、治療を求める人口が拡大しています。特に若い女性の間で、積極的な健康管理へと消費者行動が変化しており、処方薬と非処方薬の両方に対する需要が高まっています。医薬品の技術革新も、非侵襲的でホルモンを含まない選択肢を含む、より的を絞った患者に優しい治療法を導入しており、副作用を警戒する人々への訴求を広げています。世界のヘルスケア支出の増加は、発展途上地域におけるヘルスケアインフラの改善とともに、月経困難症治療へのアクセスをさらに後押ししています。ソーシャルメディア、ウェルネス・インフルエンサー、生理肯定的支持の影響も、月経健康ソリューションへの消費者の投資意欲を高めています。これらの促進要因が市場を前進させ、月経困難症治療をニッチな関心事から世界の健康上の優先事項へと変化させています。

セグメント

疾患（原発性月経困難症、続発性月経困難症）;薬剤クラス別（ホルモン治療、非ステロイド性抗炎症薬、外科手術）

調査対象企業の例（全48件）

  • Abbott Laboratories
  • AbbVie Inc.
  • Almatica Pharma
  • Alvogen, Inc.
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Endo Pharmaceuticals Inc.
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals
  • GlaxoSmithKline PLC
  • Grunenthal GmbH
  • iPulse Medical Ltd.
  • Johnson & Johnson Services, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36774

Global Dysmenorrhea Treatment Market to Reach US$9.1 Billion by 2030

The global market for Dysmenorrhea Treatment estimated at US$5.9 Billion in the year 2024, is expected to reach US$9.1 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Primary Dysmenorrhea, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$6.0 Billion by the end of the analysis period. Growth in the Secondary Dysmenorrhea segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 12.1% CAGR

The Dysmenorrhea Treatment market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Dysmenorrhea Treatment Market - Key Trends & Drivers Summarized

Why Is Dysmenorrhea No Longer Being Overlooked in Women’s Health?

For decades, dysmenorrhea-commonly known as painful menstruation-was often trivialized or underdiagnosed. Today, however, it is emerging as a significant public health concern with mounting awareness and growing healthcare interventions. Affecting more than half of menstruating individuals globally, dysmenorrhea is not only a source of discomfort but also a major cause of absenteeism from school and work. This has placed immense socio-economic pressure on healthcare systems, prompting stakeholders to reframe menstrual pain as a legitimate medical condition rather than a “normal” female experience. Public health initiatives and educational campaigns are dismantling stigma and encouraging women to seek professional help instead of relying solely on over-the-counter remedies. Additionally, social media and online platforms have amplified women’s health conversations, turning conditions like dysmenorrhea into urgent topics for research and treatment. The cumulative impact is a broader recognition of the need for structured diagnosis and targeted treatment plans, thereby energizing growth in the dysmenorrhea treatment market.

What Advances Are We Seeing in Therapeutic Options for Menstrual Pain?

The treatment landscape for dysmenorrhea has evolved significantly beyond traditional NSAIDs and oral contraceptives. While nonsteroidal anti-inflammatory drugs remain the first-line therapy for reducing prostaglandin-induced uterine contractions, new formulations are being developed for longer-lasting and faster-acting relief. Hormonal treatments are being fine-tuned to offer better tolerability and fewer side effects, making them suitable for a wider demographic of users. Moreover, there is an increasing trend toward non-hormonal therapies-especially for patients with contraindications to hormone use-ranging from transdermal patches and vaginal rings to neuromodulation devices. In parallel, research in complementary medicine is gaining ground, including the use of herbal extracts, acupuncture, and dietary supplements that have shown promise in clinical studies. Novel delivery mechanisms such as extended-release tablets, thermal patches, and drug-coated tampons are also expanding treatment accessibility and efficacy. These innovations are not only diversifying the product portfolio but also redefining how menstrual pain is managed across different population segments.

How Is the Global Market Shifting Based on Demographics and Awareness?

Demographic shifts and cultural evolution are playing pivotal roles in driving demand for dysmenorrhea treatments. Younger generations, especially Gen Z and millennials, are more health-aware and proactive about menstrual wellness, often seeking medical support rather than enduring pain silently. This behavioral shift is mirrored by healthcare providers who are now more likely to diagnose and treat dysmenorrhea as a distinct clinical entity. In developed regions like North America and Europe, advanced healthcare systems and insurance coverage support early diagnosis and treatment adherence. Meanwhile, emerging economies in Asia-Pacific, Latin America, and Africa are seeing rising demand driven by improving access to healthcare, government-led health education campaigns, and increasing numbers of gynecologists. Additionally, the urbanization of rural populations is improving access to OTC products and digital consultations, allowing women to explore treatment options more easily. Pharmaceutical companies are also intensifying marketing efforts in these regions, often tailoring their products to meet local preferences and cultural sensitivities. This geographic and demographic diversification is fostering a more inclusive and expansive market footprint.

What Forces Are Accelerating Growth in the Dysmenorrhea Treatment Market?

The growth in the dysmenorrhea treatment market is driven by several factors. Technological advances in drug formulation and delivery systems are significantly enhancing efficacy and patient compliance. The increasing diagnosis rates due to heightened awareness and destigmatization of menstrual disorders are expanding the treatment-seeking population. Shifting consumer behavior toward proactive health management, especially among younger women, is translating into stronger demand for both prescription and non-prescription therapies. Pharmaceutical innovation is also introducing more targeted and patient-friendly therapies, including non-invasive and hormone-free options, broadening appeal to those wary of side effects. Rising global healthcare spending, along with improved healthcare infrastructure in developing regions, is further boosting access to dysmenorrhea treatments. The influence of social media, wellness influencers, and period-positive advocacy is also increasing consumer willingness to invest in menstrual health solutions. Altogether, these drivers are propelling the market forward, transforming dysmenorrhea treatment from a niche concern to a global health priority.

SCOPE OF STUDY:

The report analyzes the Dysmenorrhea Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diseases (Primary Dysmenorrhea, Secondary Dysmenorrhea); Therapeutic Class (Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs, Surgery)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Abbott Laboratories
  • AbbVie Inc.
  • Almatica Pharma
  • Alvogen, Inc.
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Endo Pharmaceuticals Inc.
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals
  • GlaxoSmithKline PLC
  • Grunenthal GmbH
  • iPulse Medical Ltd.
  • Johnson & Johnson Services, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Dysmenorrhea Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Menstrual Health Issues Spurs Demand for Effective Dysmenorrhea Treatments
    • Over-the-Counter Accessibility of NSAIDs Expands Market Reach and Accelerates Adoption
    • Growth of Telehealth Services Strengthens Business Case for Remote Prescription Fulfillment
    • Hormonal Therapy Innovations and Targeted Drug Delivery Drive New Product Introductions
    • Increase in Female Workforce Participation Generates Need for Rapid Relief Solutions
    • Social Media Advocacy and Menstrual Health Campaigns Throw the Spotlight on Under-Treated Conditions
    • Plant-Based and Herbal Remedies for Dysmenorrhea Gain Popularity Among Health-Conscious Consumers
    • Growing Research into Prostaglandin Inhibitors Sustains Innovation in Drug Pipelines
    • Inclusion of Menstrual Pain in Employee Wellness Programs Expands Corporate Healthcare Market
    • Cross-Selling Opportunities in Women's Health Products Propel Market Penetration
    • Online Pharmacies and DTC Healthcare Platforms Drive Convenient Access to Dysmenorrhea Treatment
    • Expansion of Insurance Coverage in Emerging Markets Boosts Demand for Professional Diagnosis and Treatment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Dysmenorrhea Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Dysmenorrhea Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Dysmenorrhea Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Primary Dysmenorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Primary Dysmenorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Primary Dysmenorrhea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Secondary Dysmenorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Secondary Dysmenorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Secondary Dysmenorrhea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hormonal Medical Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hormonal Medical Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hormonal Medical Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Dysmenorrhea Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • JAPAN
    • Dysmenorrhea Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • CHINA
    • Dysmenorrhea Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • EUROPE
    • Dysmenorrhea Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Dysmenorrhea Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Dysmenorrhea Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • FRANCE
    • Dysmenorrhea Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • GERMANY
    • Dysmenorrhea Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Dysmenorrhea Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Dysmenorrhea Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Dysmenorrhea Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Dysmenorrhea Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Dysmenorrhea Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • INDIA
    • Dysmenorrhea Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Dysmenorrhea Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Dysmenorrhea Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Dysmenorrhea Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Dysmenorrhea Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Dysmenorrhea Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Dysmenorrhea Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030
  • AFRICA
    • Dysmenorrhea Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Dysmenorrhea Treatment by Diseases - Primary Dysmenorrhea and Secondary Dysmenorrhea Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Dysmenorrhea Treatment by Diseases - Percentage Breakdown of Value Sales for Primary Dysmenorrhea and Secondary Dysmenorrhea for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Dysmenorrhea Treatment by Therapeutic Class - Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Dysmenorrhea Treatment by Therapeutic Class - Percentage Breakdown of Value Sales for Hormonal Medical Treatment, Non-Steroidal Anti-Inflammatory Drugs and Surgery for the Years 2014, 2025 & 2030

IV. COMPETITION